5F-SDB-006
# 5F-SDB-006

5F-SDB-006 is a drug that acts as a potent agonist for the cannabinoid receptors, with an $EC_{50}$ of 50 nM for human $CB_1$ receptors, and 123 nM for human $CB_2$ receptors. It was discovered during research into the related compound APICA which had been sold illicitly as "2NE1". 5F-SDB-006 is the terminally fluorinated analog of SDB-006, just as STS-135 is the terminally fluorinated analog of APICA. Given the known metabolic liberation (and presence as an impurity) of amantadine in the related compound APINACA, it is suspected that metabolic hydrolysis of the amide group of 5F-SDB-006 may release benzylamine.

